Peregrine Completes Exclusive Worldwide License for Novel New Anti-Cancer Compounds
... licensed technology uses antibodies that target phosphatidylserine (PS) on the surface of tumor endothelial cells, which line blood vessels in tumors....... is currently in a multi-center Phase II clinical study for the treatment of brain cancer and in four Phase I clinical studies for the treatment of colorectal,...
Aug 29 1:01 PM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/bw/010829/290230.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines